Jun 2026 (Q2 FY26) — Jul 30, 2026
Fulgent Genetics Q2 FY26 — Revenue Cycle Management Challenges Impact Guidance, Clinical Pipeline Advances
Read the full callFulgent Genetics (FLGT) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Fulgent Genetics earnings: last reported Thu, 30 Jul 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 85.4 | +4.4% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -42.3 | −18.1 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -29.5 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$21.34 +1.57% · +$0.33
Performance −4.7% 1Y
1Y: $22.39 on 14 Oct 2025 → $21.34. High $30.85 (25 Nov 2025), low $13.79 (3 Mar 2026).
- Previous close
- $21.01
- 52-week range
- $13.79 – $30.85
- One year
- −6.24%
Overview
- Symbol
- FLGT
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Fulgent Genetics earnings calls (FLGT)
Financials
What the filings say
Net profit, year on year: −56% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 72 | 76 | 73 | 82 | 84 | 83 | 71 | 85 |
| Operating profit | -17 | -16 | -20 | -20 | -15 | -36 | -35 | -36 |
| Operating margin | −23.8% | −21.2% | −26.9% | −24.1% | −18.3% | −43.5% | −48.7% | −42.3% |
| Other income | -1 | 8 | 8 | -2 | 8 | 7 | 9 | 6 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | -19 | -8 | -12 | -22 | -8 | -29 | -26 | -30 |
| Tax rate | 20.7% | — | −1.5% | 10.5% | 9.1% | 19.2% | 2.7% | −0.1% |
| Net profit | -15 | -6 | -12 | -19 | -7 | -23 | -25 | -30 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -63 | -63 | 151 | 658 | 801 | 633 | 590 | 530 |
| Total liabilities | 3 | 6 | 131 | 113 | 116 | 102 | 91 | 107 |
| Fixed assets | 6 | 6 | 40 | 62 | 81 | 83 | 106 | 113 |
| Total assets | 54 | 89 | 700 | 1,279 | 1,386 | 1,235 | 1,220 | 1,214 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -1 | 6 | 141 | 539 | 254 | 27 | 21 | -102 |
| Cash from investing | 1 | -29 | -326 | -547 | -261 | 39 | -58 | 111 |
| Cash from financing | 0 | 29 | 261 | 85 | -77 | -48 | -5 | -15 |
| Net cash flow | 0 | 5 | 75 | 77 | -85 | 18 | -42 | -5 |
| Capital expenditure | -2 | -1 | -35 | -24 | -19 | -22 | -40 | -23 |
| Free cash flow | -3 | 4 | 105 | 515 | 235 | 5 | -19 | -124 |
Insider filings
87 filings between Oct 26, 2025 and Sep 2, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$677.6K
15 sales by 2 insiders
Compensation
not trading decisions- 19
- Award — granted as compensation
- 52
- Tax withheld — shares kept back by the company to cover tax
Also filed: 1 gift.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Xie Jian | — | $504.5K | Sep 2, 2026 |
| Gao Hanlin | — | $173.0K | Sep 2, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 2, 2026 | Gao Hanlin Chief Scientific Officer | Sale | 1,673 | $32.9K |
| Sep 2, 2026 | Xie Jian President and COO | Sale | 2,127 | $41.8K |
| Sep 1, 2026 | Hsieh Ming Chief Executive Officer | Tax withheld | 4,392 | $86.0K |
| Sep 1, 2026 | Kim Paul CFO and Treasurer | Tax withheld | 2,087 | $40.9K |
| Aug 27, 2026 | Xie Jian President and COO | Sale | 1,193 | $23.7K |
| Aug 27, 2026 | Gao Hanlin Chief Scientific Officer | Sale | 939 | $18.7K |
| Aug 26, 2026 | Kim Paul CFO and Treasurer | Tax withheld | 1,168 | $23.1K |
| Aug 26, 2026 | Hsieh Ming Chief Executive Officer | Tax withheld | 2,949 | $58.4K |
| Jul 26, 2026 | Kim Paul CFO and Treasurer | Tax withheld | 2,747 | $54.0K |
| Jul 26, 2026 | Gao Hanlin Chief Scientific Officer | Tax withheld | 1,645 | $32.4K |
| Jul 26, 2026 | Xie Jian President and COO | Tax withheld | 4,361 | $85.8K |
| Jun 2, 2026 | Xie Jian President and COO | Sale | 2,146 | $38.4K |
| Jun 2, 2026 | Gao Hanlin Chief Scientific Officer | Sale | 1,688 | $30.2K |
| Jun 1, 2026 | Hsieh Ming Chief Executive Officer | Tax withheld | 4,392 | $79.5K |
| Jun 1, 2026 | Kim Paul CFO and Treasurer | Tax withheld | 2,087 | $37.8K |
| May 27, 2026 | Gao Hanlin Chief Scientific Officer | Sale | 945 | $16.6K |
| May 27, 2026 | Xie Jian President and COO | Sale | 1,201 | $21.1K |
| May 26, 2026 | Kim Paul CFO and Treasurer | Tax withheld | 1,168 | $20.6K |
| May 26, 2026 | Hsieh Ming Chief Executive Officer | Tax withheld | 2,949 | $52.1K |
| May 14, 2026 | Nohaile Michael Director | Award | 5,558 | $0 |
| May 14, 2026 | Marsh Linda Director | Award | 11,117 | $0 |
| May 14, 2026 | GROVES REGINA E Director | Award | 11,117 | $0 |
| Apr 26, 2026 | Gao Hanlin Chief Scientific Officer | Tax withheld | 1,645 | $26.8K |
| Apr 26, 2026 | Xie Jian President and COO | Tax withheld | 4,361 | $71.1K |
| Apr 26, 2026 | Kim Paul CFO and Treasurer | Tax withheld | 2,747 | $44.8K |
| Mar 1, 2026 | Xie Jian President and COO | Tax withheld | 8,147 | $124.9K |
| Mar 1, 2026 | Xie Jian President and COO | Tax withheld | 1,079 | $16.5K |
| Mar 1, 2026 | Gao Hanlin Chief Scientific Officer | Tax withheld | 6,410 | $98.3K |
| Mar 1, 2026 | Gao Hanlin Chief Scientific Officer | Tax withheld | 1,018 | $15.6K |
| Mar 1, 2026 | Hsieh Ming Chief Executive Officer | Tax withheld | 17,566 | $269.3K |
| Mar 1, 2026 | Kim Paul CFO and Treasurer | Tax withheld | 1,133 | $17.4K |
| Mar 1, 2026 | Kim Paul CFO and Treasurer | Tax withheld | 8,347 | $128.0K |
| Feb 26, 2026 | Xie Jian President and COO | Tax withheld | 1,140 | $28.2K |
| Feb 26, 2026 | Kim Paul CFO and Treasurer | Tax withheld | 1,168 | $28.9K |
| Feb 26, 2026 | Gao Hanlin Chief Scientific Officer | Tax withheld | 897 | $22.2K |
| Feb 26, 2026 | Hsieh Ming Chief Executive Officer | Tax withheld | 2,949 | $73.0K |
| Feb 24, 2026 | Hsieh Ming Chief Executive Officer | Award | 39,802 | $0 |
| Feb 24, 2026 | Xie Jian President and COO | Tax withheld | 8,254 | $190.6K |
| Feb 24, 2026 | Xie Jian President and COO | Tax withheld | 3,163 | $73.0K |
| Feb 24, 2026 | Xie Jian President and COO | Award | 27,341 | $0 |
| Feb 24, 2026 | Hsieh Ming Chief Executive Officer | Award | 19,067 | $0 |
| Feb 24, 2026 | Xie Jian President and COO | Award | 5,862 | $0 |
| Feb 24, 2026 | Gao Hanlin Chief Scientific Officer | Award | 26,661 | $0 |
| Feb 24, 2026 | Gao Hanlin Chief Scientific Officer | Award | 22,806 | $0 |
| Feb 24, 2026 | Gao Hanlin Chief Scientific Officer | Tax withheld | 8,149 | $188.2K |
| Feb 24, 2026 | Xie Jian President and COO | Award | 15,299 | $0 |
| Feb 24, 2026 | Gao Hanlin Chief Scientific Officer | Tax withheld | 4,661 | $107.6K |
| Feb 24, 2026 | Gao Hanlin Chief Scientific Officer | Tax withheld | 2,489 | $57.5K |
| Feb 24, 2026 | Xie Jian President and COO | Tax withheld | 14,751 | $340.6K |
| Feb 24, 2026 | Gao Hanlin Chief Scientific Officer | Award | 12,762 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Fulgent Genetics, Inc.
Free account. Everything above stays public.
Write why you follow Fulgent Genetics, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading